MO2-16-3 - Population PK/PD Analysis of Necitumumab: Dose justification for Squamous Cell Lung Cancer (SqCLC) Patients in Japan
- Resource Type
- Abstract
- Source
- In
Annals of Oncology October 2019 30 Supplement 6:vi109-vi109 - Subject
- Language
- ISSN
- 0923-7534